Insider Buys 40,000 Shares of Black Diamond Therapeutics
Shannon Campbell purchased 40,000 shares, signaling confidence in Black Diamond Therapeutics.
Key Points
- Insider Shannon Campbell bought 40,000 shares of Black Diamond Therapeutics on June 26, 2026.
- Shares of NasdaqGS:BDTX traded near $1.75 on Tuesday, with a market cap of about $98 million.
- Analysts maintain a positive outlook with recent buy ratings and price targets as high as $14.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Shannon Campbell, an insider at Black Diamond Therapeutics, Inc. (NasdaqGS: BDTX), purchased 40,000 shares on June 26, 2026. This insider transaction did not specify a purchase price, but it reflects a notable acquisition of shares in the company.
Insider Buying and Selling at Black Diamond Therapeutics, Inc.
Several insiders, including Shannon Campbell, Garry Menzel, and Prakash Raman, each acquired 40,000 shares of Black Diamond Therapeutics on June 26, 2026. These transactions were not part of any prearranged trading plans, suggesting a direct investment decision by these insiders.
Black Diamond Therapeutics, Inc. Stock Down 21.5%
Shares of Black Diamond Therapeutics traded near $1.75 on Tuesday. The company, which operates in the biotechnology sector, has a market cap of approximately $98 million. Black Diamond Therapeutics is not currently profitable, resulting in no meaningful P/E ratio. The stock has a beta of 3.233, indicating significant volatility. Its 52-week range is between $1.60 and $4.94, with a 50-day moving average of $2.45 and a 200-day moving average of $2.85.
$BDTX stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Recent analyst activity shows continued confidence in Black Diamond Therapeutics. On April 29, 2026, BTIG maintained its buy rating with an $11 price target. Other firms, including Wedbush and Piper Sandler, have also reiterated buy ratings with targets as high as $14. The consensus target price for the stock is around $9.86, based on seven analyst opinions.
About Black Diamond Therapeutics
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company based in Cambridge, Massachusetts. It focuses on developing therapies for genetically defined tumors. The company's lead product candidate, silevertinib, is in Phase 2 trials for treating specific types of cancer. Black Diamond also has other pipeline candidates targeting various oncogenic mutations. Dr. Mark A. Velleca serves as the CEO, leading a team of 21 employees.
Bottom Line
The recent insider buying activity at Black Diamond Therapeutics is noteworthy as it reflects potential confidence in the company's future prospects. While the stock is volatile, analysts have maintained positive ratings, suggesting a favorable outlook. As always, it's important to remember that insider transactions are disclosed after they occur and may not indicate immediate changes in stock performance.
Get Black Diamond Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $BDTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.